Distribution of inpatient cost per day and total cost for patients who received autologous HCT (A-B) (n = 131) and patients with neuroblastoma (C-D) (n = 60) with TA-TMA vs no-TA-TMA. (A) With TA-TMA (n = 24) vs those without TA-TMA (n = 107), cost per day from day 15 to day 365 after HCT (P = .671). (B) With TA-TMA (n = 24) vs those without TA-TMA (n = 107), total cost from day 15 to day 365 after HCT (P = .430). (C) With TA-TMA (n = 17) vs those without TA-TMA (n = 43): cost per day from day 15 to day 365 after HCT (P = .637). (D) With TA-TMA (n = 17) vs those without TA-TMA (n = 43): total cost (P = .795).